Hinman A R
Am J Dis Child. 1986 Jun;140(6):528-30. doi: 10.1001/archpedi.1986.02140200038022.
Information provided by the three commercial manufacturers of diphtheria and tetanus toxoids and pertussis vaccine, adsorbed (DTP vaccine) indicates a striking increase in the number of lawsuits filed against them alleging damage caused by the vaccine. Only one such case was filed in 1978, whereas 73 were filed in 1984. During the seven-year period from 1978 to 1984, the average amount claimed per suit has risen from $10 million to $46.5 million. If the current trend continues, suits will pose an increasing threat to the availability of DTP vaccines in the United States.
吸附型白喉破伤风类毒素及百日咳疫苗（DTP疫苗）的三家商业制造商提供的信息表明，指控该疫苗造成损害而对他们提起诉讼的案件数量显著增加。1978年仅有1起此类案件，而1984年则有73起。在1978年至1984年的七年期间，每起诉讼的平均索赔金额已从1000万美元升至4650万美元。如果目前的趋势持续下去，诉讼将对美国DTP疫苗的供应构成越来越大的威胁。
